secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-04-22T23:59:59+00:00
Accession:  0001104659-22-048558
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022
---------------------------------------------------------------------

- CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.
- Coverage effective June 5, 2022, after a 45-day notice period as announced April 21, 2022.
- Tyvaso is a treprostinil inhalation solution marketed by United Therapeutics for pulmonary hypertension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922048558/0001104659-22-048558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922048558/tm2213312d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-048558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer